金吾财讯 | 金斯瑞生物科技(01548)公告，于2024年，归母净利录得29.62亿元（美元，下同），去年同期录得亏损9547.7万元，同比扭亏为盈，每股基本利润139.63分，来自持续经营业务每股基本亏损8.19分。董事会已决议不宣派任何股息。期内，持续经营业务整体收益5.94亿元，同比增长6.07%。收益增加主要是由于(i)持续投入商业推广（尤其在欧洲和美国）以提升品牌影响力；及(ii)推出新的竞争服务和产品，市场份额稳定增长。报告期内毛利约为272.1百万美元，较上期保持稳定。于报告期内，(i)生命科学服务及产品，(ii)生物制剂开发服务及(iii)工业合成生物产品的外部收益分别约占集团总收益的75.8%、14.8%及9.0%。期内，毛利录得2.72亿元，同比增长0.55%，经调整毛利较上期增加4.5%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.